{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:47:01Z","timestamp":1781714821350,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":346,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.7861\/clinmed.2023-rm1","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T17:25:33Z","timestamp":1685121933000},"page":"254-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The emerging pillars of chronic kidney disease: no longer a bystander in metabolic medicine"],"prefix":"10.1016","volume":"23","author":[{"given":"Alexa","family":"Wonnacott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.7861\/clinmed.2023-RM1_bib1","unstructured":"1 NHS England,. Chronic kidney disease in England: the human and financial cost. www.england.nhs.uk\/improvement-hub\/wp-content\/uploads\/sites\/44\/2017\/11\/Chronic-Kidney-Disease-in-England-The-Human-and-Financial-Cost.pdf [Accessed 19 February 23]."},{"key":"10.7861\/clinmed.2023-RM1_bib2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11606-010-1511-x","article-title":"Chronic kidney disease and the risk of end-stage renal disease versus death","volume":"26","author":"Dalrymple","year":"2011","journal-title":"J Gen Intern Med"},{"key":"10.7861\/clinmed.2023-RM1_bib3","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1681\/ASN.2008121270","article-title":"Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes","volume":"20","author":"Ninomiya","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.7861\/clinmed.2023-RM1_bib4","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmed.2023-RM1_bib5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmed.2023-RM1_bib6","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1681\/ASN.2015111230","article-title":"Anti-TGF-\u03b21 antibody therapy in patients with diabetic nephropathy","volume":"28","author":"Voelker","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.7861\/clinmed.2023-RM1_bib7","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3389\/fphar.2020.00967","article-title":"GLP-1 Receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms","volume":"11","author":"Kawanami","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.7861\/clinmed.2023-RM1_bib8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmed.2023-RM1_bib9","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmed.2023-RM1_bib10","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmed.2023-RM1_bib11","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmed.2023-RM1_bib12","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmed.2023-RM1_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmed.2023-RM1_bib14","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group","year":"2022","journal-title":"Lancet"},{"key":"10.7861\/clinmed.2023-RM1_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"10.7861\/clinmed.2023-RM1_bib16","series-title":"Clinical Practice Guideline: Sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease","year":"2021"},{"key":"10.7861\/clinmed.2023-RM1_bib17","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.kint.2018.05.026","article-title":"Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinical trials","volume":"94","author":"van Raalte","year":"2018","journal-title":"Kidney Int"},{"key":"10.7861\/clinmed.2023-RM1_bib18","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.7861\/clinmed.2023-RM1_bib19","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmed.2023-RM1_bib20","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmed.2023-RM1_bib21","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824046104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824046104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.7861\/clinmed.2023-RM1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T08:51:04Z","timestamp":1744447864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211824046104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1470211824046104"],"URL":"https:\/\/doi.org\/10.7861\/clinmed.2023-rm1","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The emerging pillars of chronic kidney disease: no longer a bystander in metabolic medicine","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.7861\/clinmed.2023-RM1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Royal College of Physicians 2023. All rights reserved.","name":"copyright","label":"Copyright"}]}}